In the second wave of psychedelic research, there are multiple trials taking place across the world.
This includes looking into their potential use to treat end-of-life anxiety and depression in the terminally ill (at the US’s John Hopkins University and NYU), for smoking cessation, alcoholism, anorexia, OCD, asthma, longevity and pain syndromes, as well as seven separate trials worldwide into the use of psilocybin to treat depression.